Genetic breakthrough drug enters human trials for silent liver killer
NCT ID NCT06322628
Summary
This study is testing an experimental drug called VSA006 in Chinese adults with nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The drug works by targeting a specific liver protein linked to disease progression. Researchers will check if the injection reduces liver fat and scarring compared to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgeng Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.